Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propolis cream, specifically the formulation containing 0.5% propolis special extract GH 2002 (marketed as Herpetino®), is a topical phytotherapeutic agent used for the treatment of herpes labialis (cold sores). Developed by Harras Pharma Curarina GmbH, this botanical extract exerts antiviral effects against both herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). In addition to its antiviral properties, the extract provides antibacterial, anti-inflammatory, and local anesthetic benefits, which collectively facilitate the healing process. Clinical evidence from Phase 3 randomized trials has demonstrated that propolis cream is superior to aciclovir 5% cream, achieving faster lesion encrustation and epithelization, typically within a median of 3 days compared to 4 days for aciclovir.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propolis special extract GH 2002.